key: cord-0924481-9wkig9fy
authors: Vaduganathan, Muthiah; Butler, Javed; Krumholz, Harlan M.; Itchhaporia, Dipti; Stecker, Eric C.; Bhatt, Deepak L.
title: Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency
date: 2020-11-24
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.09.594
sha: 48358cf6ad59785a15a08ae7ebf3c724db8d7a23
doc_id: 924481
cord_uid: 9wkig9fy

nan

With increasing political pressures, heightened public scrutiny, and building anticipation around potential therapies and vaccines targeting COVID-19, the role of regulatory authorities in guiding the evaluation of non-COVID-19 therapeutics has been less discussed. In this report, we specifically examine how COVID-19 has affected regulatory strategy and the pipeline of cardiovascular drugs and devices. More broadly, even beyond the approval of novel drugs and devices, the FDA has actively reviewed labeling changes to existing therapies. Thus far in 2020, approximately 500 cardiovascular therapies have received approvals or tentative approvals, inclusive of labeling updates (4) . The pace of these approvals has been relatively steady even during the initial phases of COVID-19 ( Figure 1 ). The work for many of these approvals, clearances, and labeling changes were far advanced by the time the pandemic began. New applications are anticipated to slow, resulting in a potential reduction in future cardiovascular therapeutics in the pipeline.

In anticipation of supply chain disruptions in access to existing therapies, the FDA is actively working with manufacturers to monitor product availability. As of supply, and study monitoring procedures. As in original study protocols, methods to handle increased anticipated data missingness or premature study discontinuation rates during the pandemic should be adapted as needed.

The regional variation in the spread of COVID-19 also introduces unique challenges. Ongoing prospective efforts are underway to harmonize capture of common patient-level and site-level data elements.

For instance, the Heart Failure Collaboratory, a public-private partnership with the FDA, is creating structured, streamlined, and standardized case report forms to capture COVID-19-related information (10) .

In global trials, as sites will be anticipated to be affected during different time periods, this information may guide sensitivity analyses to dissect regional, temporal, and treatment interactions.

Informed consent: The FDA has offered several alternative approaches to troubleshoot and 

Level Ex, Medtelligence/ReachMD (CME steering committees

Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME steering committees); has other relationships with Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Abbott

Twitter: @mva-duganathan, @JavedButler1, @hmkyale, @ditchhaporia, @DLBHATTMD

The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials

Novel Drug Approvals for 2020

Food and Drug Administration. 2020 Device Approvals

Drugs@FDA: FDA-Approved Drugs

Food and Drug Administration. Drug Shortages

Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States

FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency

Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency

Points to Consider on Implications of Coronavirus Disease (COVID-19) on

Heart Failure Collaboratory state